Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (Enhance-2)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2019
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms Enhance-2
- Sponsors Acadia Pharmaceuticals
- 15 Jun 2019 This trial has been completed in Germany , according to European Clinical Trials Database.
- 13 Nov 2017 New trial record